LON:FAB Fusion Antibodies (FAB) Share Price, News & Analysis GBX 6.89 +0.34 (+5.21%) (As of 12/20/2024 11:56 AM ET) Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsHeadlinesInsider Trades About Fusion Antibodies Stock (LON:FAB) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Fusion Antibodies alerts:Sign Up Key Stats Today's Range 6.62▼ 7.2050-Day Range 3.92▼ 7.1052-Week Range 2.80▼ 8.50Volume1.60 million shsAverage Volume1.18 million shsMarket Capitalization£6.57 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewFusion Antibodies plc, a contract research organization, engages in the research, development, and manufacture of recombinant proteins and antibodies primarily for cancer and infectious diseases in the United Kingdom, the rest of Europe, North America, and internationally. The company offers monoclonal antibody discovery and development, antibody sequencing, antibody engineering, antibody humanization and rational affinity maturation platform, recombinant protein expression, and stable cell line development and cGMP scale up services. It serves pharmaceutical, biotech, and diagnostic companies. The company has a collaboration partnership with Celonic AG. The company was incorporated in 2000 and is headquartered in Belfast, the United Kingdom.Read More… Receive FAB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Fusion Antibodies and its competitors with MarketBeat's FREE daily newsletter. Email Address FAB Stock News HeadlinesFusion Antibodies Secures Grant to Boost R&DDecember 4, 2024 | msn.comFusion Antibody Share Chat (FAB)October 26, 2024 | lse.co.ukHow to piss off your liberal friends… and profit from itElon Musk has just exposed the “energy grift” of America in a recent tweet to his platform, X. And people are slowly starting to wake up to the Deep State’s lies.December 22, 2024 | Porter & Company (Ad)'Positive momentum' builds at Belfast's Fusion AntibodiesOctober 10, 2024 | msn.comFusion Antibodies Full Year 2024 Earnings: EPS Misses ExpectationsSeptember 7, 2024 | finance.yahoo.comRevenues collapse after ‘challenging year’ at Fusion AntibodiesSeptember 5, 2024 | msn.comArtificial sun: Nuclear fusion closes in, new method can tackle key challengesAugust 26, 2024 | msn.comResearch Reveals Conserved Neutralizing Epitope in Herpesvirus gB ProteinFebruary 27, 2024 | msn.comSee More Headlines FAB Stock Analysis - Frequently Asked Questions How have FAB shares performed this year? Fusion Antibodies' stock was trading at GBX 4.25 at the start of the year. Since then, FAB shares have increased by 62.1% and is now trading at GBX 6.89. View the best growth stocks for 2024 here. How do I buy shares of Fusion Antibodies? Shares of FAB stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. What other stocks do shareholders of Fusion Antibodies own? Based on aggregate information from My MarketBeat watchlists, some other companies that Fusion Antibodies investors own include 4D pharma (DDDD), Omega Diagnostics Group (ODX), Tullow Oil (TLW), Active Energy Group (AEG), B&M European Value Retail (BME), BP (BP) and Coats Group (COA). Industry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolLON:FAB CUSIPN/A CIKN/A Webfusionantibodies.com Phone+44-28-90432800FaxN/AEmployees48Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)GBX (0.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income£-2,190,000.00 Net Margins-195.95% Pretax MarginN/A Return on Equity-152.68% Return on Assets-63.78% Debt Debt-to-Equity Ratio2.40 Current Ratio3.87 Quick Ratio2.36 Sales & Book Value Annual Sales£1.14 million Price / Sales5.76 Cash FlowGBX 0.76 per share Price / Cash Flow9.02 Book ValueGBX 2 per share Price / Book3.45Miscellaneous Outstanding Shares95,370,000Free FloatN/AMarket Cap£6.57 million OptionableNot Optionable Beta0.49 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report This page (LON:FAB) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | SponsoredThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredThis is the worst sign for the U.S. stock market in 50 yearsThe Dow recently posted its worst losing streak since 1974. And one of America's most accurate analysts no...Stansberry Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | SponsoredWhy Buffett, Griffin and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fusion Antibodies plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Fusion Antibodies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.